Added to YB: 2025-09-22
Pitch date: 2025-09-18
TNG.PA [bullish]
Transgene SA
-17.93%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Market Cap
EUR 145.6M
Pitch Price
EUR 1.16
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Transgene (TNG France): extending runway while advancing immunotherapy pipeline
TNG.PA (quick overview): French biotech advancing TG4050 personalized cancer vaccine through phase II head/neck trials. Phase II randomization completing end-2025, immunological data 2026, efficacy results 2027. Funding extended to end-2026, cash burn moderating. BT-001 melanoma program showing tumor shrinkage. Focused viral vector immunotherapy platform with few competitors.
Read full article (1 min)